Quetiapine Leads to Hyperosmolar Hyperglycemic State in a Nonagenarian
Abstract
Behavioral and psychological symptoms of dementia (BPSD) are present in the vast majority of patients with dementia. Quetiapine, a second-generation antipsychotic used off-label for BPSD, has been associated with adverse metabolic effects in older adults. Despite this, there are no specific guidelines on monitoring serum glucose or lipids after initiation of antipsychotics. We describe a case of hyperosmolar hyperglycemic state (HHS) likely precipitated by quetiapine in an older adult with BPSD. In this patient without a prior history of diabetes, quetiapine likely led to increased insulin resistance and subsequent HHS. Infection and acute ischemia, which commonly precipitate HHS, were absent. This patient had risk factors for diabetes, including a previously elevated random blood glucose level and obesity. Review of encounters preceding hospitalization revealed no symptoms to suggest poorly controlled diabetes. Quetiapine and other antipsychotics associated with metabolic syndrome should be used cautiously in older adults. Routine glucose monitoring is important.
Citation: Ann Longterm Care. 2022.
DOI: 10.25270/altc.2022.03.002
Received September 22, 2020; accepted January 28, 2021.
Published online March 24, 2022.
References
1. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73. doi:10.3389/fneur.2012.00073
2. Hersch EC, Falzgraf S. Management of the behavioral and psychological symptoms of dementia. Clin Interv Aging. 2007;2(4):611‐621. doi:10.2147/cia.s1698
3. Afram B, Stephan A, Verbeek H, et al. Reasons for institutionalization of people with dementia: informal caregiver reports from 8 European countries. J Am Med Dir Assoc. 2014;15(2):108-116. doi:10.1016/j.jamda.2013.09.012
4. Azermai M, Petrovic M, Elseviers MM, Bourgeois J, Van Bortel LM, Vander Stichele RH. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Res Rev. 2012;11(1):78-86. doi:10.1016/j.arr.2011.07.002
5. Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr. 2010;22(3):346-372. doi:10.1017/S1041610209991505
6. Khan SS, Singer BD, Vaughan DE. Molecular and physiological manifestations and measurement of aging in humans. Aging Cell. 2017;16(4):624‐633. doi:10.1111/acel.12601
7. Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of metabolic pathways in aging. Diabetes. 2012;61(6):1315‐1322. doi:10.2337/db11-1300
8. Kushner JA. The role of aging upon ß cell turnover. J Clin Invest. 2013;123(3):990‐995. doi:10.1172/JCI64095
9. Kuk JL, Saunders TJ, Davidson LE, Ross R. Age-related changes in total and regional fat distribution. Ageing Res Rev. 2009;8(4):339-348. doi: 10.1016/j.arr.2009.06.001
10. Lumeng CN, Liu J, Geletka L, et al. Aging is associated with an increase in T cells and inflammatory macrophages in visceral adipose tissue. J Immunol. 2011;187(12):6208-6216. doi:10.4049/jimmunol.1102188
11. Chen J, Huang XF, Shao R, Chen C, Deng C. Molecular mechanisms of antipsychotic drug-induced diabetes. Front Neurosci. 2017;11:643. doi:10.3389/fnins.2017.00643
12. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51(8):480-491. doi:10.1177/070674370605100803
13. El-Saifi N, Moyle W, Jones C, Tuffaha H. Quetiapine safety in older adults: a systematic literature review. J Clin Pharm Ther. 2016;41(1):7-18. doi:10.1111/jcpt.12357
14. Chen WY, Chen CC, Hung GC. Hyperglycemic hyperosmolar state associated with low-dose quetiapine treatment in a patient with bipolar disorder. Curr Drug Saf. 2011;6(3):207-208.
doi: 10.2174/157488611797579276